Latest News
Genesis Biotechnology Group Acquires Comparative Biosciences, to add GLP Toxicology and Safety Pharmacology
Monday 10 August 2020

US-based Genesis Biotechnology Group's Genesis Drug Discovery and Development CRO business has acquired US-based contract research organization Comparative Biosciences, Inc., the company said.

CBI is specialized in GLP (Good Laboratory Practice) Toxicology and Safety Pharmacology projects for IND-enabling research studies.

This portfolio addition will enable GD3 to expand its pre-clinical services to GLP based studies by offering integrated, single-point-of-contact services throughout the project lifetime, streamlining all phases of the discovery cycle and enabling new discoveries to progress rapidly from project inception through pre-clinical development.

CBI's skilled team of scientists, will work synergistically with GD3's existing services around preclinical drug discovery.

Comparative Biosciences is a preclinical contract research organisation It provides scientific resources and contract research services to all sectors of the biomedical and biopharmaceutical community.

Its team of scientists has extensive experience in GLP and non-GLP preclinical toxicology, efficacy, pharmacology, pharmacokinetics-pharmacodynamics, histopathology, and safety studies on all laboratory species.

CBI's particular areas of expertise including ocular, dermatology, fibrosis, ototoxicity, wound healing and burns, stem cells, oncology, renal, inflammation, immune-mediated, CNS, cardiovascular, infection models, devices, contract histopathology, immunohistochemistry, and custom model development.

Genesis biotechnology Group is a consortium of vertically-integrated companies, in the fields of drug discovery, personalised and tailored clinical diagnostics, and through the development, manufacturing, and distribution of unique biotechnology-based products.

Genesis Drug Discovery and Development is a fully integrated CRO focused on providing services to support preclinical drug discovery programs from early discovery through preclinical development.
Date Published: 10/08/2020